<DOC>
	<DOCNO>NCT02103699</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness simeprevir-containing hepatitis C virus ( HCV ) treatment regimen measure sustained virologic response ( SVR ) .</brief_summary>
	<brief_title>A Study Examine Patient Characteristics , Health Care Management Health Outcomes Hepatitis C Virus ( HCV ) Patients Treated With Simeprevir</brief_title>
	<detailed_description>This multicenter , observational ( study investigators/ physician observe patient measure outcome ) , prospective study ( study patient identify follow forward time outcome study ) design reflect routine clinical practice . Approximately 300 Hepatitis C virus ( HCV ) infect patient prescribe simeprevir health care provider part routine HCV treatment regimen , inclusive patient treat simeprevir-based therapy less equal ( &lt; = ) 28 day enrol observed evaluate effectiveness simeprevir . Practice set feature document initiation study participate site . The decision patient participate study way impact upon standard care receive . All treatment decision make discretion health care provider . Safety assessment include assessment adverse event , clinical laboratory parameter ( hematology , clot test , human immunodeficiency virus test , chemistry , liver function test ) . The maximum study duration patient approximately 2 year .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Patients genotype 1 chronic hepatitis C infection Hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) test result limit quantification initiation simeprevirbased therapy Health care provider decision treat patient simeprevirbased therapy , inclusive patient treat simeprevirbased therapy less equal ( &lt; = ) 28 day enrol study Prior HCV treatment must complete 3 month initiation simeprevirbased therapy In opinion health care provider , patient attend routine standard care visit , either enrol site virtual/telemedicine Nongenotype 1 HCV infect patient Absolute contraindication component prescribe HCV treatment per prescribe information Patient currently enrol interventional study Past use HCV directacting antiviral therapy Any investigational drug use within 30 day initiation simeprevirbased therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Ribonucleic acid</keyword>
	<keyword>Sustained virologic response</keyword>
</DOC>